Select Page
Alzheimer’s disease

Alzheimer’s disease

Alzheimer disease, AD Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by the presence in the central nervous system of extracellular amyloid beta (Aβ) plaques, intracellular neurofibrillary tangles, translating into memory defects...
NanoSIRNA

NanoSIRNA

NanosiRNA® COVID-19: specific antiviral treatment Medesis Pharma has a microemulsion technology that enables it to deliver these non-modified native siRNAs directly into the cytoplasm of all the organism’s cells via the HDL lipoprotein receptors, crossing the...
NanoManganese

NanoManganese

Medesis Pharma is developing a radioprotection drug to treat people irradiated following a civil or military nuclear accident (NP02 – NanoManganese®). Preclinical trials have been carried out with the French Armed Forces Biomedical Research Institute (IRBA)....
Viral diseases

Viral diseases

Medesis Pharma is developing a radioprotection drug to treat people irradiated following a civil or military nuclear accident (NP02 – NanoManganese®). Preclinical trials have been carried out with the French Armed Forces Biomedical Research Institute (IRBA). (Study...
Nuclear radioprotection drug

Nuclear radioprotection drug

The objective of the radioprotection program is to develop a radiomitigation drug, administered in the minutes / hours following an overexposure to ionizing radiation. It will be used for the treatment of civilian and military personnel (dual technology) exposed...
Cesium decorporation

Cesium decorporation

NU02 Cesium decorporation 137Cs is gamma and beta emitting by-product of uranium fission. Large quantities of 137Cs were released into the atmosphere during the Chernobyl and Fukushima disasters. 137Cs is water soluble and therefore can travel large distances from the...